Cardiac Risk Assessment in Modern Oncology-Not Optional Anymore

Guest Contribtions, Heart First /

On the occasion of Heart Month, this blog aims to highlight what cardio-oncology truly offers to both physicians and patients, specifically in terms of cardiac assessment and surveillance. Today, there are millions of cancer survivors living with short- and long-term cardiovascular complications related to their cancer therapies. Caring for this growing population is no longer […]

Cardiac Risk Assessment in Modern Oncology-Not Optional Anymore Read More »

Cervical Cancer: What Patients and Clinicians Should Know

Guest Contribtions, Heart First /

An expert Q&A with Dr. Tashanna Myers, Gynecologic Oncologist Introduction: Why Cervical Cancer Still Matters Cervical cancer remains one of the most preventable yet still devastating cancers affecting women worldwide. According to the World Health Organization, it is the fourth most common cancer in women globally, with approximately 600,000 new cases and 350,000 deaths in

Cervical Cancer: What Patients and Clinicians Should Know Read More »

Ghee (Clarified Butter): Tradition, Chemistry, and Cardiovascular Implications

Heart First /

Clarified butter, or ghee, has been used for cooking and medicinal purposes for millennia, particularly in the Indian subcontinent. Over time, its use spread to the Middle East, Central Asia, parts of Africa, and more recently to the Americas. Today, ghee is often promoted as a “heart-healthy” traditional fat—but tradition alone does not determine metabolic

Ghee (Clarified Butter): Tradition, Chemistry, and Cardiovascular Implications Read More »

Collateral Damage: Anthracycline-Related Cardiac Injury in Blood Cancers

Heart First /

Anthracyclines remain a cornerstone of therapy for many hematologic malignancies, owing to their potent cytotoxic effects on rapidly proliferating cancer cells. However, their use is limited by well-recognized cardiotoxicity, which can manifest across a broad temporal spectrum and significantly affect long-term morbidity and mortality among cancer survivors. Patterns and Incidence of Cardiotoxicity Anthracycline-associated cardiotoxicity is

Collateral Damage: Anthracycline-Related Cardiac Injury in Blood Cancers Read More »

From Cure to Care: Cardiovascular Surveillance in Hodgkin’s Lymphoma

Heart First /

Hodgkin’s lymphoma (HL) is one of oncology’s greatest success stories, with high cure rates and long-term survival—especially in early-stage disease. However, this success has uncovered an important reality: in patients with early Hodgkin’s lymphoma, cardiovascular disease becomes the leading cause of death in the long term, surpassing cancer-related mortality. Understanding and mitigating this risk is

From Cure to Care: Cardiovascular Surveillance in Hodgkin’s Lymphoma Read More »

Before the First Dose: Why the Heart Matters in Cancer Care

Heart First /

Cancer and cardiovascular disease are the two leading causes of morbidity and mortality worldwide. Both are non-communicable diseases that frequently coexist and share overlapping risk factors, including hypertension, diabetes, obesity, hyperlipidemia, smoking, and sedentary lifestyle. As cancer survival improves, the cardiovascular consequences of cancer and its therapies have become increasingly relevant. Despite this, cardio-oncology is

Before the First Dose: Why the Heart Matters in Cancer Care Read More »